Stephen J. Haggarty, Ph.D., is
an Instructor of Neurology at Harvard Medical
School and Assistant in Neuroscience at
the Massachusetts General Hospital. He is
also the director of the Chemical Neurobiology
Laboratory (CNL) within the Stanley Center
for Psychiatric Research at the Broad Institute.
Dr. Haggarty graduated from The University
of British Columbia, Vancouver in 1997 with
a degree in Genetics and received his Ph.D.
from Harvard University in 2003, for his
work developing methodology for high-throughput
chemical screening and the identification
of small-molecule probes of the cell cycle
and chromatin remodeling. Dr. Haggarty then
joined the Broad Institute of Massachusetts
Institute of Technology and Harvard University,
as a research Fellow in the Chemical Biology
Program and member of the Psychiatric Disease
Initiative.
Dr. Haggarty’s current research
interests focuses on using chemical approaches
to understanding the molecular and genetic
basis of neuropsychiatric and neurodegenerative
disorders, including schizophrenia, bipolar
disorder, and Huntington’s disease.
The overall aims of his research group and
the CNL are three-fold: 1) the development
of novel cellular and biochemical assays
for screening small molecules, RNAi, and
cDNA libraries in order to identify probes
targeting neuropsychiatric and neurodegenerative
disease-relevant mechanisms and pathways;
2) the identification of targets and functional
characterization of new molecular probes
using the appropriate counter screens, proteomics
and biochemical assays in neuronal cells
and brain tissue models; and 3) through
collaborators around the world, to characterize
the function of candidate susceptibility
genes and to test new mechanisms of action
compounds in animal behavioral models involving
the response to psychoactive drugs, memory,
and disease-relevant mutations.
|
